Home LiteratureArticle Details

PMID: 3709620 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

European journal of clinical pharmacology ·Vol. 29 ·No. 6 ·1986-00-00 ·Pages 739-41

Leemann T, Dayer P, Meyer UA

Abstract

暂无摘要

MeSH Terms

Adult Debrisoquin/metabolism Depression, Chemical Humans Metoprolol/metabolism Oxidation-Reduction Quinidine/administration & dosage,pharmacology Stereoisomerism

Chemicals

Metoprolol Quinidine Debrisoquin

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Leemann T

Dayer P

Meyer U A

References (14)

14 references, click to expand

Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
FEBS Lett. 1984 Aug 6;173(2):287-90 PMID: 6146537
The genetic control of bufuralol metabolism in man.
Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):73-7 PMID: 6121708
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
Life Sci. 1980 Nov 3;27(18):1673-7 PMID: 7442467
Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.
Life Sci. 1984 Jan 2;34(1):73-80 PMID: 6141510
[Polymorphisms and deficient drug metabolism as triggers of toxic reactions (author's transl)].
Arzneimittelforschung. 1977;27(96):1836-44 PMID: 579150
Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.
Biochem Biophys Res Commun. 1984 Nov 30;125(1):374-80 PMID: 6508804
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
J Med Genet. 1980 Apr;17(2):102-5 PMID: 7381862
Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.
Eur J Clin Pharmacol. 1985;28(2):149-53 PMID: 2859203
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers.
Clin Pharmacol Ther. 1983 Dec;34(6):732-7 PMID: 6641087
Polymorphic hydroxylation of Debrisoquine in man.
Lancet. 1977 Sep 17;2(8038):584-6 PMID: 71400
Quinidine-induced rise in ajmaline plasma concentration.
J Pharm Pharmacol. 1984 Mar;36(3):202-4 PMID: 6144760
Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
Proc Natl Acad Sci U S A. 1984 Dec;81(23):7348-52 PMID: 6594694
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
Br J Clin Pharmacol. 1982 Aug;14(2):301-3 PMID: 6125207
Oxidation polymorphism has clinical relevance.
Lancet. 1984 Jul 28;2(8396):227 PMID: 6146783

Article Info

Journal

European journal of clinical pharmacology

Abbr.

Eur J Clin Pharmacol

ISSN

0031-6970

DOI

10.1007/BF00615971

Published

1986-00-00

Pages

739-41

Language

English

Region

Germany

NLM ID

1256165

Subset

External Links

PubMed source DOI: 10.1007/BF00615971 View journal details

Analysis Services

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Contact

WeChat Official Account